Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71353 | 1.00 | SCD (0.45) | SCDGPR119FFAR1RXRAGRIN1 | |
| SCHEMBL70415 | 0.87 | SCD (0.41) | SCDGPR119FFAR1 | |
| SCHEMBL29382077 | 0.87 | SCD (0.41) | SCDGPR119FFAR1 | |
| SCHEMBL68925 | 0.86 | SCD (0.59) | SCDGPR119 | |
| SCHEMBL29382371 | 0.86 | SCD (0.59) | SCDGPR119 | |
| SCHEMBL29384724 | 0.85 | SCD (0.43) | SCD | |
| SCHEMBL70209 | 0.85 | SCD (0.43) | SCD | |
| SCHEMBL68333 | 0.82 | USP30 (0.49) | SCDGPR119GRIN1GRIN2BNAMPT | |
| SCHEMBL29385527 | 0.82 | USP30 (0.49) | SCDGPR119GRIN1GRIN2BNAMPT | |
| SCHEMBL67882 | 0.81 | GPR6 (0.40) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885GPR119 4121/4885FFAR1 4529/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD 1194/4885GPR119 4121/4885FFAR1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.